New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project., Journal of Clinical Oncology, vol.16, issue.8, pp.2780-2795, 1998. ,
DOI : 10.1200/JCO.1998.16.8.2780
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20, Blood, vol.83, pp.435-445, 1994. ,
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program., Journal of Clinical Oncology, vol.16, issue.8, pp.2825-2833, 1998. ,
DOI : 10.1200/JCO.1998.16.8.2825
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial, Blood, vol.108, issue.10, pp.3295-3301, 2006. ,
DOI : 10.1182/blood-2006-05-021113
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG), Blood, vol.108, issue.13, pp.4003-4008, 2006. ,
DOI : 10.1182/blood-2006-04-016725
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma, Blood, vol.90, pp.2188-2195, 1997. ,